TW202229328A - 抗原特異性抗體之鑑定及產生 - Google Patents
抗原特異性抗體之鑑定及產生 Download PDFInfo
- Publication number
- TW202229328A TW202229328A TW110133845A TW110133845A TW202229328A TW 202229328 A TW202229328 A TW 202229328A TW 110133845 A TW110133845 A TW 110133845A TW 110133845 A TW110133845 A TW 110133845A TW 202229328 A TW202229328 A TW 202229328A
- Authority
- TW
- Taiwan
- Prior art keywords
- human
- light chain
- chain variable
- heavy chain
- gene segments
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B35/20—Screening of libraries
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/122—Massive parallel sequencing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Library & Information Science (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077133P | 2020-09-11 | 2020-09-11 | |
| US202063077140P | 2020-09-11 | 2020-09-11 | |
| US63/077,133 | 2020-09-11 | ||
| US63/077,140 | 2020-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202229328A true TW202229328A (zh) | 2022-08-01 |
Family
ID=78078424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110133845A TW202229328A (zh) | 2020-09-11 | 2021-09-10 | 抗原特異性抗體之鑑定及產生 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220090060A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4211155A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7883483B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066386A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021342159A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3187680A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301137A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202229328A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022056276A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025193757A1 (en) * | 2024-03-12 | 2025-09-18 | Pacific Biosciences Of California, Inc. | Methods and systems for masking an array of biosensor elements |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US419A (en) | 1837-10-06 | Machine fob boring and mortising wheel-hubs and other articles | ||
| US5932A (en) | 1848-11-21 | brown | ||
| US5789A (en) | 1848-09-19 | Improvement in fountain-pen holders and nibs | ||
| US166A (en) | 1837-04-17 | Standing press | ||
| US5071A (en) | 1847-04-17 | George page | ||
| US743A (en) | 1838-05-17 | Improvement in plows | ||
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5702931A (en) | 1991-07-01 | 1997-12-30 | Berlex Laboratories, Inc. | Mutagenesis methods and compositions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6242222B1 (en) | 1996-06-07 | 2001-06-05 | Massachusetts Institute Of Technology | Programmed sequential mutagenesis |
| US5780270A (en) | 1996-07-17 | 1998-07-14 | Promega Corporation | Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity |
| EP1972194A1 (en) * | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7795494B2 (en) | 2001-03-22 | 2010-09-14 | Abbott Laboratories | Transgenic mice expressing antibodies specific for genes of interest and uses thereof |
| MXPA05002514A (es) | 2002-09-06 | 2005-05-27 | Amgen Inc | Anticuerpo monoclonal anti-il-1r1 humano terapeutico. |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP1776383B1 (en) | 2004-07-22 | 2014-08-20 | Erasmus University Medical Center Rotterdam | Binding molecules |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| KR101703299B1 (ko) | 2007-06-01 | 2017-02-06 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물 |
| EP2088432A1 (en) * | 2008-02-11 | 2009-08-12 | MorphoSys AG | Methods for identification of an antibody or a target |
| EP3456191A1 (en) | 2008-06-27 | 2019-03-20 | Merus N.V. | Antibody producing non-human mammals |
| PL2346994T3 (pl) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Myszy knock-in do wytwarzania chimerycznych przeciwciał |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| CN103989487B (zh) | 2009-10-20 | 2016-04-20 | 柯尼卡美能达医疗印刷器材株式会社 | 放射线图像摄影系统 |
| WO2011072204A1 (en) | 2009-12-10 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130185821A1 (en) * | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| PL3248462T3 (pl) | 2010-03-31 | 2024-07-08 | Ablexis, Llc | Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych |
| CN103228130B (zh) | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
| MY195217A (en) | 2010-06-22 | 2023-01-11 | Regeneron Pharma | MICE Expressing An Immunoglobulin Hybrid Light Chain |
| CN103025884B (zh) | 2010-07-26 | 2015-11-25 | 特里安尼公司 | 转基因动物和使用方法 |
| EP2601298B1 (en) | 2010-08-02 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| CN105861548B (zh) | 2011-02-25 | 2020-01-10 | 瑞泽恩制药公司 | Adam6小鼠 |
| ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
| AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| EP4074833A1 (en) | 2011-10-17 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| SMT201900296T1 (it) * | 2011-12-20 | 2019-07-11 | Regeneron Pharma | Topi di catena leggera umanizzata |
| RU2664185C2 (ru) | 2012-02-01 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl |
| JP2015509380A (ja) | 2012-03-06 | 2015-03-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通の軽鎖のマウス |
| HUE037659T2 (hu) | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására |
| US9801362B2 (en) | 2012-03-16 | 2017-10-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
| WO2013138681A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| SG11201405059XA (en) | 2012-03-28 | 2014-09-26 | Kymab Ltd | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
| SG10201609535TA (en) | 2012-06-05 | 2017-01-27 | Regeneron Pharma | Methods for making fully human bispecific antibodies using a common light chain |
| NZ703689A (en) | 2012-06-12 | 2016-05-27 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| RS57582B1 (sr) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| KR20150126863A (ko) | 2013-03-13 | 2015-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 공통 경쇄 마우스 |
| MY191512A (en) | 2013-09-18 | 2022-06-28 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| AU2015230938C1 (en) | 2014-03-21 | 2021-10-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| PL3209698T5 (pl) | 2014-10-22 | 2022-04-25 | Crescendo Biologics Limited | Mysz transgeniczna |
| CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
| EP3402571A4 (en) | 2016-01-15 | 2019-08-28 | The J. David Gladstone Institutes | METHOD FOR THE TREATMENT OF DISORDERS BY METABOLIC CONTROL OF T-CELL DIFFERENTIATION |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| WO2017214211A1 (en) * | 2016-06-09 | 2017-12-14 | Igc Bio, Inc. | Methods for identifying a high affinity antibody |
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| EP4567119A3 (en) | 2016-11-04 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| GB201710984D0 (en) | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
| WO2019113065A1 (en) | 2017-12-05 | 2019-06-13 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| EP3897117A1 (en) | 2018-12-21 | 2021-10-27 | Compass Therapeutics LLC | Transgenic mouse expressing common human light chain |
| WO2020169022A1 (en) | 2019-02-18 | 2020-08-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animals with humanized immunoglobulin locus |
| PT3979790T (pt) | 2019-06-05 | 2026-05-05 | Regeneron Pharma | Roedores possuindo um reportrio limitado de cadeias leves lambda expressadas a partir do lcus kappa e suas utilizaes |
-
2021
- 2021-09-10 US US17/472,132 patent/US20220090060A1/en active Pending
- 2021-09-10 KR KR1020237011476A patent/KR20230066386A/ko active Pending
- 2021-09-10 CA CA3187680A patent/CA3187680A1/en active Pending
- 2021-09-10 AU AU2021342159A patent/AU2021342159A1/en active Pending
- 2021-09-10 EP EP21786711.8A patent/EP4211155A1/en active Pending
- 2021-09-10 WO PCT/US2021/049887 patent/WO2022056276A1/en not_active Ceased
- 2021-09-10 TW TW110133845A patent/TW202229328A/zh unknown
- 2021-09-10 IL IL301137A patent/IL301137A/en unknown
- 2021-09-10 JP JP2023516124A patent/JP7883483B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023540808A (ja) | 2023-09-26 |
| WO2022056276A1 (en) | 2022-03-17 |
| IL301137A (en) | 2023-05-01 |
| KR20230066386A (ko) | 2023-05-15 |
| US20220090060A1 (en) | 2022-03-24 |
| JP7883483B2 (ja) | 2026-07-01 |
| CA3187680A1 (en) | 2022-03-17 |
| EP4211155A1 (en) | 2023-07-19 |
| AU2021342159A1 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12291798B2 (en) | Generation of binding molecules | |
| AU2021283564B2 (en) | Genetically modified non-human animals with common light chain immunoglobulin locus | |
| KR102033659B1 (ko) | 샘플과 연관된 폴리뉴클레오티드의 식별 | |
| US11365260B2 (en) | Agonistic 4-1BB monoclonal antibody | |
| AU2022287551A1 (en) | Mixed binding domains | |
| CA2841475A1 (en) | Identifying affinity-matured human antibodies | |
| EP3367786A1 (en) | Transgenic rabbit with common light chain | |
| US20220090060A1 (en) | Identification and production of antigen-specific antibodies | |
| RU2858215C2 (ru) | Индентификация и продуцирование антиген-специфических антител | |
| CN117015302A (zh) | 抗原特异性抗体的鉴定和产生 | |
| WO2026046369A1 (zh) | 产生限制的免疫球蛋白轻链库的细胞、动物和方法 |